MAIA Biotechnology, Inc. (MAIA) Key Metrics
MAIA valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $67.9M
- Enterprise value
- $52.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.9 10-yr median 20.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.28
MAIA key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMAIA valuation Price multiples at each fiscal year-end price.
MAIA returns How much profit the business earns on the capital it uses.
MAIA per-share figures Results divided by the shares outstanding at year-end.
MAIA financial health Debt, liquidity and how easily interest is covered.
MAIA valuation history
MAIA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MAIA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MAIA cash returned to shareholders
MAIA price vs earnings per share
MAIA key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $49.1M | $44.0M | $15.5M | — | — | — | — |
| Enterprise value | −$8.61B | $34.3M | $8.4M | — | — | — | — |
| Price / book | 20.7 | 12.1 | 32.5 | — | — | — | — |
| Earnings yield | −45.6% | −52.9% | −127.4% | — | — | — | — |
| Free cash flow yield | −38.4% | −35.7% | −84.2% | — | — | — | — |
| Share price at fiscal year-end | $1.53 | $1.98 | $1.17 | $3.51 | — | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Earnings per share | −$0.70 | −$1.05 | −$1.49 | — | — | — | — |
| Operating cash flow per share | −$0.59 | −$0.71 | −$0.99 | — | — | — | — |
| Free cash flow per share | −$0.59 | −$0.71 | −$0.99 | — | — | — | — |
| Cash per share | $269.59 | $0.43 | $0.54 | — | — | — | — |
| Book value per share | $0.07 | $0.16 | $0.04 | — | — | — | — |
| Tangible book value per share | $0.07 | $0.16 | $0.04 | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Shares outstanding | 32.1M | 22.2M | 13.3M | — | — | — | — |
| Change in shares outstanding | +44.7% | +67.4% | — | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −745.2% | — | −440.1% | −178.3% | −427.8% | — | — |
| Return on assets (ROA) | −225.5% | −262.4% | −201.9% | −135.1% | −207.1% | −535.0% | −374.3% |
| Return on tangible assets | −230.8% | −229.0% | −261.3% | −131.2% | −110.4% | −889.0% | −374.3% |
| Financial health | |||||||
| Total debt | — | — | — | — | $111,271 | $463,754 | $34,172 |
| Cash & short-term investments | $8.66B | $9.6M | $7.2M | $11.0M | $10.6M | $663,457 | $1.7M |
| Net debt | −$8.66B | −$9.6M | −$7.2M | −$11.0M | −$10.5M | −$199,703 | −$1.7M |
| Debt / equity | — | — | — | — | 0.01 | — | — |
| Debt / assets | — | — | — | — | 0.01 | 0.62 | 0.02 |
| Current ratio | 1.66 | 2.65 | 1.53 | 3.61 | 4.97 | 0.44 | 4.63 |
| Quick ratio | 1.66 | 2.65 | 1.53 | 3.61 | 4.99 | 0.44 | 4.63 |
| Interest coverage | — | — | — | — | -9.4 | -221.1 | — |
| Working capital | $3.9M | $6.3M | $2.6M | $8.5M | $8.5M | −$947,239 | $1.4M |
| Invested capital | −$8.66B | −$6.0M | −$6.7M | −$2.4M | −$1.3M | −$3.5M | −$1.8M |
| Tangible asset value | $2.4M | $3.6M | $477,511 | $8.5M | $9.2M | −$1.6M | $1.3M |
| Net current asset value | $2.4M | $3.6M | $474,711 | $8.3M | $8.5M | −$1.6M | $1.3M |
| Graham net-net per share | $269.37 | $0.14 | $0.01 | — | — | — | — |
| Capital allocation | |||||||
| Dividends paid | — | — | — | — | — | $58,212 | — |
| Share buybacks (net) | — | — | — | — | — | $58,212 | — |
| Capex / depreciation | — | 0.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | |||||||
| Receivables turnover | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | $111,014 | $223,734 | $173,228 | $43,666 | — | — |
| Average payables | $1.8M | $1.6M | $1.4M | $1.1M | $557,644 | $162,037 | $169,188 |
| Average inventory | — | — | — | — | −$43,666 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from MAIA's annual financial statements (latest annual report filed March 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MAIA valuation and financial ratios
MAIA Biotechnology earned a return on equity of −745.2% in fiscal 2025.
See the MAIA income statement, the MAIA chart for price history, or the MAIA stock overview for the latest quote and news.
MAIA key metrics FAQ
What is MAIA Biotechnology's return on equity?
MAIA Biotechnology's return on equity (ROE) was −745.2% in fiscal 2025: net income of -$22.4 million on average shareholders' equity of $3.0 million.
What is MAIA Biotechnology's free cash flow yield?
MAIA Biotechnology generated -$18.8 million of free cash flow in fiscal 2025, a free cash flow yield of −38.4% on its market value at year-end ($49.1 million).
What is MAIA Biotechnology's current ratio?
MAIA Biotechnology's current ratio was 1.66 at the end of fiscal 2025: current assets were 1.66 times current liabilities.